JO25567 is a multicentre, open-label, randomised, phase 2 study that evaluated the erlotinib single agent or with bevacizumab as a first-line treatment in patients with advanced NSCLC and common EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.